---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-24-000086"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:05:00.558899+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q2 2024 net income $49.2M; cash $354.5M; Chiesi collaboration on track

## Summary
- Net income $49.2M ($0.22 basic EPS) vs net loss $42.5M in Q2 2023.
- Cash, cash equivalents & marketable securities $354.5M as of June 30, 2024; runway into H1 2027.
- Revenue from Chiesi collaboration: $88.8M license sale + $7.1M R&D services.
- R&D expenses $35.1M (vs $36.3M); G&A expenses $8.7M (vs $10.0M).
- PROSERA Phase 3 PAH trial enrollment ongoing; top-line results expected Q4 2025; Phase 3 PH-ILD trial to start mid-2025.

## SEC filing metadata
- accession: 0001728117-24-000086
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000086/0001728117-24-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000086/goss-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-24-000086
- JSON: https://secwatch.observer/filing/0001728117-24-000086.json
- Plain text: https://secwatch.observer/filing/0001728117-24-000086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.